ConductScience.org, home

Trial · NCT01182766

Results by group33

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Continuous Smoking Abstinence in the Last 4 Weeks of Treatment Continuous Smoking Abstinence in the Last 4 Weeks of TreatmentPlacebo2participants
Continuous Smoking Abstinence in the Last 4 Weeks of Treatment Continuous Smoking Abstinence in the Last 4 Weeks of TreatmentLow-Dose Topiramate5participants
Continuous Smoking Abstinence in the Last 4 Weeks of Treatment Continuous Smoking Abstinence in the Last 4 Weeks of TreatmentHigh-Dose Topiramate6participants
Percentage of Heavy Drinking Days (PHDD) in the Last 4 Weeks of TreatmentPlacebo62.8Standard Deviation 45.4percentage of heavy drinking days
Percentage of Heavy Drinking Days (PHDD) in the Last 4 Weeks of TreatmentLow-Dose Topiramate65.1Standard Deviation 44percentage of heavy drinking days
Percentage of Heavy Drinking Days (PHDD) in the Last 4 Weeks of TreatmentHigh-Dose Topiramate59.3Standard Deviation 47.3percentage of heavy drinking days
Quality of Life in the Last 4 Weeks of TreatmentPlaceboCoursework40.2Standard Deviation 6.9percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentLow-Dose TopiramateCoursework37.1Standard Deviation 10.3percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentHigh-Dose TopiramateCoursework35.4Standard Deviation 14.4percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentPlaceboGeneral Activities57.7Standard Deviation 8.7percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentLow-Dose TopiramateGeneral Activities54.2Standard Deviation 10.7percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentHigh-Dose TopiramateGeneral Activities57.9Standard Deviation 8.6percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentPlaceboHousehold Duties43.6Standard Deviation 5.1percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentLow-Dose TopiramateHousehold Duties42Standard Deviation 7.2percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentHigh-Dose TopiramateHousehold Duties41.6Standard Deviation 8.7percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentPlaceboPhysical Health25.2Standard Deviation 3.7percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentLow-Dose TopiramatePhysical Health24.1Standard Deviation 4.9percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentHigh-Dose TopiramatePhysical Health23.4Standard Deviation 5.5percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentPlaceboSocial Relations51.7Standard Deviation 8.4percent score on a scale
Quality of Life in the Last 4 Weeks of TreatmentLow-Dose TopiramateSocial Relations50.4Standard Deviation 10.3percent score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01182766/results